Axsome Therapeutics
AXSM
172.97
-1.37
-0.79%
Axsome Therapeutics
US · AXSM
#1533 by market cap
Listed 2015
172.97
-1.37
-0.79%
Live - 5344 symbols - heartbeat 5s ago
· 2026-10-08 05:31
Pre-market
174.31
+0.77%
After-hours
172.97
0.00%
Overnight
172.59
-0.22%
- Market cap
- 9.06B
- P/E (TTM)i
- -46.13
- P/Bi
- 108.79
- EPSi
- -3.68
- Div yieldi
- 0.00%
- 52W posi
- 38%
Reader sentiment
Are you bullish or bearish on AXSM?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 15 analysts
Buy
Avg price target
288.57 +66.8%
Price target rangecurrent 172.97
Low247.00
Avg288.57
High380.00
Buy 93%
Hold 7%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-01 | Wells Fargo | -- | BUY | 256.00 |
| 2026-09-29 | Deutsche Bank | -- | BUY | 267.00 |
| 2026-09-25 | Morgan Stanley | -- | HOLD | 247.00 |
| 2026-09-25 | H.C. Wainwright | -- | BUY | 290.00 |
| 2026-09-23 | Truist Financial | -- | BUY | 285.00 |
| 2026-09-21 | H.C. Wainwright | -- | BUY | 290.00 |
| 2026-09-18 | Piper Sandler | -- | BUY | 258.00 |
| 2026-09-18 | RBC Capital | -- | BUY | 297.00 |
| 2026-09-14 | BMO Capital | -- | BUY | 310.00 |
| 2026-09-11 | Mizuho Securities | -- | BUY | 316.00 |
| 2026-09-10 | Wells Fargo | -- | BUY | 256.00 |
| 2026-09-02 | Wells Fargo | -- | BUY | 256.00 |
| 2026-09-01 | RBC Capital | -- | BUY | 297.00 |
| 2026-08-31 | H.C. Wainwright | -- | BUY | 290.00 |
| 2026-08-24 | H.C. Wainwright | -- | BUY | 290.00 |
| 2026-08-18 | Piper Sandler | -- | BUY | 258.00 |
| 2026-08-12 | Mizuho Securities | -- | BUY | 316.00 |
| 2026-08-11 | Wells Fargo | -- | BUY | 256.00 |
| 2026-08-11 | Jefferies | -- | BUY | 380.00 |
| 2026-08-10 | TD Cowen | -- | BUY | 315.00 |
| 2026-08-10 | Wells Fargo | -- | BUY | 256.00 |
| 2026-08-10 | William Blair | -- | BUY | -- |
| 2026-08-10 | BofA Securities | -- | BUY | 276.00 |
| 2026-08-10 | Morgan Stanley | -- | HOLD | 251.00 |
| 2026-08-10 | Needham | -- | BUY | 268.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 0 upgrades vs 1 downgrade among tracked analyst rating changes.
- Most recent: Morgan Stanley moved from Buy to Hold on 2026-01-08.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-01-08 | Morgan Stanley | BUY → HOLD | 204.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-10 | -- | ±8.79% | +3.83% (in line) |
| 2026/Q1 | 2026-05-04 | -- | ±5.99% | +8.31% (beat) |
| 2025/Q4 | 2026-02-23 | -- | ±7.60% | -4.88% (in line) |
| 2025/Q3 | 2025-11-03 | -- | ±7.47% | +0.56% (in line) |
| 2025/Q2 | 2025-08-04 | -- | ±8.91% | +3.42% (in line) |
| 2025/Q1 | 2025-05-05 | -- | ±9.42% | +3.81% (in line) |
| 2024/Q4 | 2025-02-18 | -- | ±7.68% | -2.33% (in line) |
| 2024/Q3 | 2024-11-12 | -- | ±9.77% | +9.35% (in line) |
| 2024/Q2 | 2024-08-05 | -- | ±11.19% | -1.43% (in line) |
| 2024/Q1 | 2024-05-06 | -- | ±9.37% | +1.52% (in line) |
| 2023/Q4 | 2024-02-20 | -- | ±12.67% | -12.57% (in line) |
| 2023/Q3 | 2023-11-06 | -- | ±9.24% | -4.18% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 05:31:53 · For reference only, not investment advice and not tailored to your situation.